Together with Matthew Meyerson, he initiated and developed large-scale efforts to re-sequence genes in diverse cancer types, which led to the development of the widely used GISTIC algorithm, the discovery of EGFR mutations in lung adenocarcinoma and the discovery of the oncogenic role of the MITF gene in melanoma. in Biology from the University of Illinois, a B.A.

bluebird bio | 55,201 followers on LinkedIn | We #RecodeForLife | At bluebird bio, we’re pioneering the uniquely promising world of gene therapy with a deep sense of purpose – to ensure lives are lived fully. Guarda il profilo completo su LinkedIn e scopri i collegamenti di Nicoletta e le offerte di lavoro presso aziende simili. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Together with Matthew Meyerson, he initiated and developed large-scale efforts to re-sequence genes in diverse cancer types, which led to the development of the widely used GISTIC algorithm, the discovery of EGFR mutations in lung adenocarcinoma and the discovery of the oncogenic role of the MITF gene in melanoma.

Referrals increase your chances of interviewing at bluebird bio by 2x15+ years of relevant experience leading a global human resources operation, ideally in the financial services sector. Prior to Merck, she was vice president of strategic transactions at Pfizer, Inc. Joanne holds a Ph.D. in Physics from the Catholic University of America, and a B.S. has served as a member of our board since September 2019.

Gary Fortin, PhD, became the Vice President & Franchise Head for Severe Genetic Diseases in September 2018. She is a member of the Michigan Bar Association.Links to sites outside of this website are provided as a resource to the viewer. in History and Philosophy of Science at Cambridge University, and received his Ph.D. in molecular biology at Trinity College at Cambridge and the MRC Laboratory of Molecular Biology.David P. Schenkein, M.D., has served as a member of our board of directors since April 2013. from the University of Massachusetts Medical School in 1986. Since October 2007, Mr. Lynch has advised and served as executive chair or member of the board of directors for a number of private biopharmaceutical companies, which include Stromedix, Inc. (until its acquisition by Biogen Idec in February 2012), Avila Therapeutics, Inc. (until its acquisition by Celgene Corporation in February 2012), Translate Bio, Inc. (formerly known as RaNA Therapeutics, Inc.), Nimbus Discovery, LLC, Edimer Pharmaceuticals, Ember Therapeutics, Inc., Proclara Biosciences, Inc., and Surface Oncology, Inc.

and Ph.D. from the University of Cambridge (UK).Nick Leschly has served as our chief bluebird since September 2010. Dr. Alison is currently a member of the board of directors of the Alliance for Regenerative Medicine Foundation which fosters education and research to support the development of transformational treatments and cures for patients worldwide. Dave received his M.D. From 1999 to 2006, Jason was a corporate and securities attorney at Ropes & Gray LLP. Sellers currently leads a research group focused on translating genomic discoveries into new therapeutics as a Core Institute Member at the Broad Institute of MIT and Harvard, and as a Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. She got her start in the healthcare industry working as an analytical chemist at Pfizer.

She was also a Fellow in Biomedical & Chemical Engineering at The Harvard-MIT Division for Health Science & Technology (Dr. Robert Langer’s Lab) where she received the NIH National Service Award in Research.Kathy Wilkinson joined us in 2012 as a senior director of human resources, and since joining us, she has overseen our growth from 38 employees to over 800 while building and fostering a culture we love – passionate, fun and relentlessly focused on patients and our people. Denice received a Bachelor of Science in Psychology from Ball State University, Doctor of Jurisprudence from Indiana University, and Master’s in Business Administration from the University of Michigan. Sellers was previously an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE. You will conduct ...What we look for. Surgeon General, and numerous other public health offices and programs.